Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Other Non Operating Income (2021 - 2025)

Prime Medicine's Other Non Operating Income history spans 5 years, with the latest figure at $49000.0 for Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 13.95% year-over-year to $49000.0; the TTM value through Dec 2025 reached $148000.0, up 260.98%, while the annual FY2025 figure was $148000.0, 260.98% up from the prior year.
  • Other Non Operating Income reached $49000.0 in Q4 2025 per PRME's latest filing, up from $44000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $2.1 million in Q1 2023 to a low of -$83000.0 in Q3 2024.
  • Average Other Non Operating Income over 5 years is $248333.3, with a median of $42500.0 recorded in 2023.
  • Peak YoY movement for Other Non Operating Income: skyrocketed 72900.0% in 2022, then plummeted 293.02% in 2024.
  • A 5-year view of Other Non Operating Income shows it stood at $12000.0 in 2021, then skyrocketed by 7616.67% to $926000.0 in 2022, then tumbled by 84.02% to $148000.0 in 2023, then tumbled by 70.95% to $43000.0 in 2024, then rose by 13.95% to $49000.0 in 2025.
  • Per Business Quant, the three most recent readings for PRME's Other Non Operating Income are $49000.0 (Q4 2025), $44000.0 (Q3 2025), and $18000.0 (Q2 2025).